KKR, Novartis, Pfizer In Race To Acquire Strides' Unit
by Paritosh Gajjar
Strides Arcolabs' injectable-drugs unit, @Agila_Specialties Private Limited is up for sale and 'serious bidders' for the asset are Novartis and @Pfizer_Limited along with U.S buyout fund KKR, ET stated.
Strides is expecting to receive anywhere between $1.6-2 Bn for the unit - more than twice its market value.
Strides provides Pfizer with generic versions of off-patent drugs through a partnership announced in 2010.
DealCurry tracks financial and corporate markets for events, interprets and integrates the information in our platform, providing premium data, news and analytics. DealCurry provides comprehensive coverage of the capital markets through an intuitive, user-friendly interface.